195 related articles for article (PubMed ID: 38657050)
1. The fatty liver disease-causing protein PNPLA3-I148M alters lipid droplet-Golgi dynamics.
Sherman DJ; Liu L; Mamrosh JL; Xie J; Ferbas J; Lomenick B; Ladinsky MS; Verma R; Rulifson IC; Deshaies RJ
Proc Natl Acad Sci U S A; 2024 Apr; 121(18):e2318619121. PubMed ID: 38657050
[TBL] [Abstract][Full Text] [Related]
2. The fatty liver disease-causing protein PNPLA3-I148M alters lipid droplet-Golgi dynamics.
Sherman DJ; Liu L; Mamrosh JL; Xie J; Ferbas J; Lomenick B; Ladinsky MS; Verma R; Rulifson IC; Deshaies RJ
bioRxiv; 2023 Oct; ():. PubMed ID: 37873239
[TBL] [Abstract][Full Text] [Related]
3. Exploring the impact of the PNPLA3 I148M variant on primary human hepatic stellate cells using 3D extracellular matrix models.
Caon E; Martins M; Hodgetts H; Blanken L; Vilia MG; Levi A; Thanapirom K; Al-Akkad W; Abu-Hanna J; Baselli G; Hall AR; Luong TV; Taanman JW; Vacca M; Valenti L; Romeo S; Mazza G; Pinzani M; Rombouts K
J Hepatol; 2024 Jun; 80(6):941-956. PubMed ID: 38365182
[TBL] [Abstract][Full Text] [Related]
4. Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women.
Cherubini A; Ostadreza M; Jamialahmadi O; Pelusi S; Rrapaj E; Casirati E; Passignani G; Norouziesfahani M; Sinopoli E; Baselli G; Meda C; Dongiovanni P; Dondossola D; Youngson N; Tourna A; Chokshi S; Bugianesi E; ; Della Torre S; Prati D; Romeo S; Valenti L
Nat Med; 2023 Oct; 29(10):2643-2655. PubMed ID: 37749332
[TBL] [Abstract][Full Text] [Related]
5. PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis.
Chen LZ; Xin YN; Geng N; Jiang M; Zhang DD; Xuan SY
World J Gastroenterol; 2015 Jan; 21(3):794-802. PubMed ID: 25624712
[TBL] [Abstract][Full Text] [Related]
6. Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin-Like Phospholipase Domain Containing 3-Mediated Acceleration of Steatohepatitis.
Banini BA; Kumar DP; Cazanave S; Seneshaw M; Mirshahi F; Santhekadur PK; Wang L; Guan HP; Oseini AM; Alonso C; Bedossa P; Koduru SV; Min HK; Sanyal AJ
Hepatology; 2021 Apr; 73(4):1290-1306. PubMed ID: 33131062
[TBL] [Abstract][Full Text] [Related]
7. Identification and Optimization of a Minor Allele-Specific siRNA to Prevent PNPLA3 I148M-Driven Nonalcoholic Fatty Liver Disease.
Murray JK; Long J; Liu L; Singh S; Pruitt D; Ollmann M; Swearingen E; Hardy M; Homann O; Wu B; Holder JR; Sham K; Herberich B; Lo MC; Dou H; Shkumatov A; Florio M; Rulifson IC
Nucleic Acid Ther; 2021 Oct; 31(5):324-340. PubMed ID: 34297902
[TBL] [Abstract][Full Text] [Related]
8. Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice.
Lindén D; Ahnmark A; Pingitore P; Ciociola E; Ahlstedt I; Andréasson AC; Sasidharan K; Madeyski-Bengtson K; Zurek M; Mancina RM; Lindblom A; Bjursell M; Böttcher G; Ståhlman M; Bohlooly-Y M; Haynes WG; Carlsson B; Graham M; Lee R; Murray S; Valenti L; Bhanot S; Åkerblad P; Romeo S
Mol Metab; 2019 Apr; 22():49-61. PubMed ID: 30772256
[TBL] [Abstract][Full Text] [Related]
9. Impact of PNPLA3 I148M on alpha-1 antitrypsin deficiency-dependent liver disease progression.
Volkert I; Fromme M; Schneider C; Candels L; Lindhauer C; Su H; Thorhauge K; Pons M; Mohamed MR; Schneider KM; Strnad P; Trautwein C
Hepatology; 2024 Apr; 79(4):898-911. PubMed ID: 37625151
[TBL] [Abstract][Full Text] [Related]
10. PNPLA3-I148M: a problem of plenty in non-alcoholic fatty liver disease.
Basu Ray S
Adipocyte; 2019 Dec; 8(1):201-208. PubMed ID: 31062641
[TBL] [Abstract][Full Text] [Related]
11. Synergistic Associations of PNPLA3 I148M Variant, Alcohol Intake, and Obesity With Risk of Cirrhosis, Hepatocellular Carcinoma, and Mortality.
Kim HS; Xiao X; Byun J; Jun G; DeSantis SM; Chen H; Thrift AP; El-Serag HB; Kanwal F; Amos CI
JAMA Netw Open; 2022 Oct; 5(10):e2234221. PubMed ID: 36190732
[TBL] [Abstract][Full Text] [Related]
12. Long-term hypercaloric diet exacerbates metabolic liver disease in PNPLA3 I148M animals.
Su H; Haque M; Becker S; Edlund K; Duda J; Wang Q; Reißing J; Marschall HU; Candels LS; Mohamed M; Sjöland W; Liao L; Drexler SA; Strowig T; Rahnenführer J; Hengstler JG; Hatting M; Trautwein C
Liver Int; 2023 Aug; 43(8):1699-1713. PubMed ID: 37073116
[TBL] [Abstract][Full Text] [Related]
13. PNPLA3 downregulation exacerbates the fibrotic response in human hepatic stellate cells.
Rady B; Nishio T; Dhar D; Liu X; Erion M; Kisseleva T; Brenner DA; Pocai A
PLoS One; 2021; 16(12):e0260721. PubMed ID: 34879108
[TBL] [Abstract][Full Text] [Related]
14. The Role of
Liu M; Park S
Nutrients; 2024 Apr; 16(8):. PubMed ID: 38674929
[TBL] [Abstract][Full Text] [Related]
15. PNPLA3 mediates hepatocyte triacylglycerol remodeling.
Ruhanen H; Perttilä J; Hölttä-Vuori M; Zhou Y; Yki-Järvinen H; Ikonen E; Käkelä R; Olkkonen VM
J Lipid Res; 2014 Apr; 55(4):739-46. PubMed ID: 24511104
[TBL] [Abstract][Full Text] [Related]
16. Modeling PNPLA3-Associated NAFLD Using Human-Induced Pluripotent Stem Cells.
Tilson SG; Morell CM; Lenaerts AS; Park SB; Hu Z; Jenkins B; Koulman A; Liang TJ; Vallier L
Hepatology; 2021 Dec; 74(6):2998-3017. PubMed ID: 34288010
[TBL] [Abstract][Full Text] [Related]
17. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells.
Pirazzi C; Valenti L; Motta BM; Pingitore P; Hedfalk K; Mancina RM; Burza MA; Indiveri C; Ferro Y; Montalcini T; Maglio C; Dongiovanni P; Fargion S; Rametta R; Pujia A; Andersson L; Ghosal S; Levin M; Wiklund O; Iacovino M; Borén J; Romeo S
Hum Mol Genet; 2014 Aug; 23(15):4077-85. PubMed ID: 24670599
[TBL] [Abstract][Full Text] [Related]
18. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis.
He S; McPhaul C; Li JZ; Garuti R; Kinch L; Grishin NV; Cohen JC; Hobbs HH
J Biol Chem; 2010 Feb; 285(9):6706-15. PubMed ID: 20034933
[TBL] [Abstract][Full Text] [Related]
19. IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease.
Park J; Zhao Y; Zhang F; Zhang S; Kwong AC; Zhang Y; Hoffmann HH; Bushweller L; Wu X; Ashbrook AW; Stefanovic B; Chen S; Branch AD; Mason CE; Jung JU; Rice CM; Wu X
J Hepatol; 2023 Jan; 78(1):45-56. PubMed ID: 36049612
[TBL] [Abstract][Full Text] [Related]
20. PNPLA3 I148M Polymorphism in Patients with Nonalcoholic Fatty Liver Disease, Obesity and Prediabetes.
Karamfilova V; Gateva A; Assyov Y; Alexiev A; Savov A; Yaneva N; Ivanova I; Ivanova-Boyanova R; Ivanova R; Vlahova Z; Mateva L; Kamenov Z
J Gastrointestin Liver Dis; 2019 Dec; 28(4):433-438. PubMed ID: 31826069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
